22
Apr
2020
Massachusetts Biotechs Consider How to Return Safely, and Create a New Normal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Apr
2020
Build Back Better
As the nation has struggled to cope with the devastation of the COVID-19 pandemic, New York Governor Andrew Cuomo has become the voice so many have looked to for support and leadership. What Cuomo seems both to offer and effectively communicate is not just a mastery of the facts, but also a grounded yet hopeful narrative. The story he projects... Read More
21
Apr
2020
How to Navigate the Blizzard of COVID-19 Antibody Studies
What is the single thing you wish you knew about COVID-19? Here is what I wonder about most. How many of us have had it already without knowing it – either because we did not have symptoms, or because we thought it was something else, or because we thought it might be COVID-19 but we could not get tested?... Read More
21
Apr
2020
Singapore’s COVID19 Crisis: Forgetting to Check the Blind Spot
It is with a heavy heart that I pen this follow-up piece on Singapore’s COVID19 situation. In the past few months, the city state has been hailed as an exemplar of early, preemptive and targeted response to combat the pandemic. Other countries have studied its response. As I wrote here on Mar. 19, despite being a densely populated high-risk state,... Read More
20
Apr
2020
Cultivating a Tolerance for Adversity in Our Teams and Our Communities
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Apr
2020
The Real Question is How to Restart
When?? When can we finally go back to something resembling a “normal” life, go back to work and restart our economies, embrace again long-lost family, friends, co-workers? And, in too many cases, when can we get together to properly mourn those we have lost? I cannot tell you “when.” Everyone wants the answer to that question. I do, too. But... Read More
17
Apr
2020
Getting it Right: Walking the Diagnostic and Serologic Testing Tightrope
Last week I felt like I was coming down with something. My throat hurt and I had a bit of a dry cough. A dreadful feeling set in. Obviously, I had COVID-19. My mother and her partner, both in their 70s, are currently living with me in Seattle. My friend’s son had recently returned from New York. A few days... Read More
17
Apr
2020
Hunting for Antibodies Against COVID19: George Scangos on The Long Run
Today’s guest on The Long Run is George Scangos. George is the CEO of San Francisco-based VIR Biotechnology. VIR has been all over the news the past couple months. It’s at the forefront of companies racing to discover and develop broadly neutralizing antibodies against the SARS-CoV-2 virus that’s sparked a global pandemic. VIR was founded in early 2017 by some... Read More
17
Apr
2020
Bridging the Social Divide in the Pandemic
Halfway through an explanation to a patient I am treating for a suspected case of COVID-19, I realize I don’t know the Spanish term for “sanitizing wipes.” I’m in my new clinical home base, where Massachusetts General Hospital has cordoned off special care for COVID-19 patients. There are modular plastic walls and bright fluorescent lights. A few weeks ago, this... Read More
16
Apr
2020
Serology Testing: Keep an Eye Out for Quick-and-Dirty Tests
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Apr
2020
Scaling Up Biotech Drugs and Vaccines Against COVID19 Won’t Be Easy
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Apr
2020
Don’t Waste this Crisis: Solving the Patient Cost-Share Problem
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Apr
2020
Drug Repurposing to Keep COVID19 Patients Out of the ICU
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Apr
2020
A Healthcare Investor, and Doctor, Peering into the Fog
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Apr
2020
Why COVID-19 Can’t Be Directly Compared With the Flu
A few years ago, I was preparing for a live radio interview about prostate cancer screening, my main area of research for the past 20 years. As a statistician focused on getting the numbers right, I disagreed strongly with the new national recommendation from an influential task force that guides practice and reimbursement. Members of that task force argued against... Read More
14
Apr
2020
The Pandemic Takes A Certain Kind of Toll on African Americans
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Apr
2020
GSK Partners With Vir on Antibodies, Pfizer With BioNTech on Vaccines, & the Testing Fiasco Continues
Here we are heading into Easter Weekend. We’re the wealthiest country in the world, and the undisputed superpower of biomedicine. Yet we’re still playing a game of catch up against SARS-CoV-2, which apparently our intelligence community knew was emerging around Thanksgiving. Even after months to get our act together, we still don’t have a coordinated national strategy on exactly how... Read More
8
Apr
2020
Facing the Consequences of a Misinformation Pandemic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Apr
2020
George Yancopoulos, That Rarest Of Species – A Physician-Scientist Still In Charge Of A Pharma
Growing up in an academic household (my parents are both professors at Yale Medical School, still engaged, as ever, in dyslexia research), it was perhaps inevitable that, outside of my parents, my first role model was the brilliant President of Yale University, the late Bart Giamatti (you know- Paul’s dad). The elder Giamatti inspired me so much as a teenager... Read More
7
Apr
2020
Rationale for Testing Anticoagulants Against COVID19
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.